Hyderabad: Hyderabad-based specialty biopharmaceutical manufacturer, Celon Laboratories, launched an alternative drug-Amphotericin B Emulsion, for the treatment of Mucormycosis, commonly known as Black Fungus. The drug is set to be made available in the market from next Monday onwards.
Amphotericin B is crucial to the treatment of Mucormycosis, of which a sudden resurgence is being witnessed off late among Covid-19 patients, across India. Though Celon has been manufacturing Liposomal Amphotericin B since 2013, market demands were not met due to the unavailability of a critical ingredient sourced from Germany— lipoids.
To bypass the bottleneck caused by this sourcing obstacle and increase production of this medication, Celon developed an alternative, an emulsion-based formulation. The drug whose pricing is not yet revealed, uses Amphotericin B as a bulk drug besides soybean oil, egg lecithin and glycerin.
Exhaustively developed by Celon’s in-house R & D team in a record three weeks, the emulsion-based formulation will provide hospitals and Covid-19 treatment centres with increased resources to treat the Black Fungus.
Celon will manufacture 10,000 vials per day, which will ensure relief for approximately 6,000 patients monthly.
Celon Labs’ MD M Nagesh Kumar, said, “The emulsion-based formulation is an ideal alternative to Liposomal Amphotericin B to combat the Black Fungus. The company will start supplying to the domestic market soon.”
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.